Asia Pacific RNAi Therapeutics Market Forecast to 2027 - COVID-19 Impact and Regional Analysis By Molecule Type (Small Interfering RNAs (siRNA) and MicroRNA (miRNA)), Application (Genetic Disorders, Oncology, Neurodegenerative Disorders, Cardiovascular, Respiratory Disorders, Infectious Diseases, Renal Diseases, and Others), Route of Administration (Intradermal Injections, Pulmonary Delivery, Intravenous Injections, Intraperitoneal Injections, and Others), and End User (Diagnostic Laboratories, Research and Academic Laboratories, and Hospitals) and Geography

Publication Month: Oct 2020 | Report Code: TIPRE00015147 | No. of Pages: 133 | Category: Biotechnology | Status: Published
Covid

 

The Asia Pacific RNAi therapeutics market is expected to reach US$ 218.64 million by 2027 from US$ 107.63 million in 2019. The market is estimated to grow at a CAGR of 9.3% from 2020 to 2027.

Growing investments in RNAi therapies and rising prevalence of infectious diseases & chronic conditions in Asia Pacific are the key factors driving the growth of RNAi therapeutics. However, high cost of RNAi therapies is the major factor hindering the market growth in Asia Pacific.

 

RNAi refers to the interference RNA which is responsible to control and manipulate protein translation in the cell. These RNAi are used to silence particular genes which are responsible for diseases. Currently, the awareness about RNAi is increasing extensively due to its ability to offer target specific mechanism, leading to superior treatment outcomes. The approach is widely utilized for drug development. Increasing number of investments in RNAi therapy development coupled with growing prevalence of infectious diseases and chronic conditions are anticipated to drive the Asia Pacific RNAi Therapeutics market during the forecast period.

 

Continuous R&D activities in RNAi therapeutics have revealed its benefits in tackling a range of chronic disorders, such as genetic conditions, renal disorders, neurodegenerative conditions, and oncology. The effectiveness of outcomes of RNAi therapies is generating investments in the development of new drugs. For instance, in June 2020, OliX Pharmaceuticals signed an agreement with LGC Biosearch technologies to accelerate production of asymmetric siRNA for the treatment of sub-retinal fibrosis and wet macular degeneration. Also, NantVentures made a private investment in public Australia based biotech Benitec Biopharma. Furthermore, Benitech and NantVentures, with the help of NantWorks, plan to begin an oncology-focused R&D collaboration with clinical development and preclinical evaluation that is to be led by Benitec. Moreover, in July 2018, Axovant Sciences signed a gene therapy licensing and development deal with Benitec Biopharma. As part of the deal, Axovant Sciences made an upfront payment of US$ 10 million to Benitec, which is also eligible for additional payments based on regulatory, development, and commercial sales milestones. Such investments help biotech and pharma companies not only launch new products but also increase number of approved products. The market players are gaining investments in the R&D of new drugs, therapies, and technologies. These increasing investments in RNAi therapeutics are driving the growth of the market.

 

Countries in Asia Pacific are severely affected by the COVID-19 outbreak. Several companies operating in this region are developing therapies for COVID-19. South Korea based OliX Pharmaceuticals, Inc., a leading developer of RNA interference (RNAi), announced that it would leverage previous preclinical research for developing siRNA therapeutics in treating respiratory illnesses to investigate a path forward for developing a COVID-19 therapy. Such continuous developments of RNAi therapies in Asia Pacific are likely to propel the market growth in this region.

 

Rest of Asia Pacific RNAi Therapeutics Market, Revenue, and Forecast to 2027 (US$ Million)

Rest of Asia Pacific RNAi Therapeutics Market, Revenue, and Forecast to 2027 (US$ Million)

Get more information on this report :


 

Asia Pacific RNAi Therapeutics Market Segmentation

 

By Molecule Type

  • Small Interfering RNAs (siRNA)
  • MicroRNA (miRNA)

 

By Route of Administration

  • Pulmonary Delivery
  • Intravenous Injections
  • Intradermal Injections
  • Intraperitoneal Injections
  • Others

 

By Application

  • Oncology
  • Cardiovascular
  • Respiratory Disorders
  • Renal Diseases
  • Genetic Disorders
  • Neurodegenerative Disorders
  • Infectious Diseases
  • Others

 

By End User

  • Research and Academic Laboratories
  • Hospitals
  • Diagnostic Laboratories

 

By Country

  • Japan
  • China
  • India
  • South Korea
  • Australia

 

Company Profiles

  • Benitec Biopharma
  • GlaxoSmithKline plc
  • Olix Pharmaceuticals, Inc.
  • Alnylam Pharmaceuticals, Inc.
  • Arrowhead Pharmaceuticals, Inc.

1.          Introduction

1.1        Scope of the Study

1.2        The Insight Partners Research Report Guidance

1.3        Market Segmentation

1.3.1        Asia Pacific RNAi Therapeutics Market – By Molecule Type

1.3.2        Asia Pacific RNAi Therapeutics Market – By Application

1.3.3        Asia Pacific RNAi Therapeutics Market – By Route of Administration

1.3.4        Asia Pacific RNAi Therapeutics Market– By End User

1.3.5        Asia Pacific RNAi Therapeutics Market – By Country

2.          Asia Pacific RNAi Therapeutics Market – Key Takeaways

3.          Research Methodology

3.1        Coverage

3.2        Secondary Research

3.3        Primary Research

4.          Asia Pacific RNAi Therapeutics Market – Market Landscape

4.1        Overview

4.2        PEST Analysis

4.2.1        RNAi therapeutics Market - Asia Pacific PEST Analysis

4.3        Expert Opinion

5.          Asia Pacific RNAi Therapeutics Market - Key Market Dynamics

5.1        Key Market Drivers

5.1.1        Growing Investments in RNAi Therapies

5.1.2        Rising Prevalence of Chronic Conditions and Infectious Diseases

5.2        Market Restraints

5.2.1        High Cost for RNAi Therapy Development

5.3        Market Opportunities

5.3.1        Significant Number of Pipeline Candidates for Strategic Alliances

5.4        Future Trends

5.4.1        Rising Emphasis on RNA Technologies

5.5        Impact analysis

6.          RNAi Therapeutics Market – Asia Pacific Analysis

6.1        Asia Pacific RNAi Therapeutics Market Revenue Forecasts and Analysis

7.          Asia Pacific RNAi Therapeutics Market Analysis and Forecasts To 2027 – By Molecule Type

7.1        Overview

7.2        Asia Pacific RNAi Therapeutics Market, By Molecule Type 2019 & 2027 (%)

7.2.1        Asia Pacific RNAi therapeutics Market Revenue and Forecasts to 2027, By Molecule Type (US$ Mn)

7.3        Small Interfering RNAs (siRNA)

7.3.1        Overview

7.3.2        Asia Pacific Small Interfering RNAs (siRNA) Market Revenue and Forecast to 2027 (US$ Mn)

7.4        MicroRNA (miRNA)

7.4.1        Overview

7.4.2        Asia Pacific MicroRNA (miRNA) Market Revenue and Forecasts to 2027 (US$ Mn)

8.          Asia Pacific RNAi therapeutics Market Analysis and Forecasts To 2027 – By Application

8.1        Overview

8.2        Asia Pacific RNAi therapeutics Market, By Application 2019 & 2027 (%)

8.2.1        Asia Pacific RNAi therapeutics Market Revenue and Forecasts to 2027, By Application (US$ Mn)

8.3        Genetic Disorders

8.3.1        Overview

8.3.2        Asia Pacific Genetic Disorders Market Revenue and Forecast to 2027 (US$ Mn)

8.4        Oncology

8.4.1        Overview

8.4.2        Asia Pacific Oncology Market Revenue and Forecasts to 2027 (US$ Mn)

8.5        Neurodegenerative Disorders

8.5.1        Overview

8.5.2        Asia Pacific Neurodegenerative Disorders Market Revenue and Forecasts to 2027 (US$ Mn)

8.6        Cardiovascular Disorders

8.6.1        Overview

8.6.2        Asia Pacific Cardiovascular Disorders Market Revenue and Forecasts to 2027 (US$ Mn)

8.7        Respiratory Disorders

8.7.1        Overview

8.7.2        Asia Pacific Respiratory Disorders Market Revenue and Forecasts to 2027 (US$ Mn)

8.8        Infectious Diseases

8.8.1        Overview

8.8.2        Asia Pacific Infectious Diseases Market Revenue and Forecasts to 2027 (US$ Mn)

8.9        Renal Diseases

8.9.1        Overview

8.9.2        Asia Pacific Renal Diseases Market Revenue and Forecasts to 2027 (US$ Mn)

8.10      Other Disorders

8.10.1     Overview

8.10.2     Asia Pacific Other Disorders Market Revenue and Forecasts to 2027 (US$ Mn)

9.          Asia Pacific RNAi therapeutics Market Analysis and Forecasts To 2027 – By Route of Administration

9.1        Overview

9.2        Asia Pacific RNAi therapeutics Market, By Route of Administration 2019 & 2027 (%)

9.2.1        Asia Pacific RNAi therapeutics Market Revenue and Forecasts to 2027, By Route of Administration (US$ Mn)

9.3        Intradermal Injections

9.3.1        Overview

9.3.2        Asia Pacific Intradermal Injections Market Revenue and Forecast to 2027 (US$ Mn)

9.4        Pulmonary Delivery

9.4.1        Overview

9.4.2        Asia Pacific Pulmonary Delivery Market Revenue and Forecasts to 2027 (US$ Mn)

9.5        Intravenous Injections

9.5.1        Overview

9.5.2        Asia Pacific Intravenous Injections Market Revenue and Forecasts to 2027 (US$ Mn)

9.6        Intraperitoneal Injections

9.6.1        Overview

9.6.2        Asia Pacific Intraperitoneal Injections Market Revenue and Forecasts to 2027 (US$ Mn)

9.7        Other Route of Administrations

9.7.1        Overview

9.7.2        Asia Pacific Other Route of Administrations Market Revenue and Forecasts to 2027 (US$ Mn)

10.       Asia Pacific RNAi Therapeutics Market Analysis – By End-User

10.1      Overview

10.2      Asia Pacific RNAi Therapeutics Market, By End-User 2019-2027 (%)

10.2.1     Asia Pacific RNAi Therapeutics Market Revenue and Forecasts to 2027, By End-User (US$ Mn)

10.3      Diagnostic Laboratories

10.3.1     Overview

10.3.2     Asia Pacific Diagnostic Laboratories Market Revenue and Forecasts to 2027 (US$ Mn)

10.4      Research and Academic Laboratories

10.4.1     Overview

10.4.2     Asia Pacific Research and Academic Laboratories Market Revenue and Forecasts to 2027 (US$ Mn)

10.5      Hospitals

10.5.1     Overview

10.5.2     Asia Pacific Hospitals Market Revenue and Forecasts to 2027 (US$ Mn)

11.       RNAi therapeutics Market Revenue and Forecasts To 2027 – Geographical Analysis

11.1      Asia Pacific: RNAi Therapeutics Market

11.1.1     Overview

11.1.2     Asia Pacific: RNAi Therapeutics Market - Revenue and Forecast to 2027 (USD Million)

11.1.3     Asia Pacific: RNAi Therapeutics Market, by Molecule Type, 2018–2027 (USD Million)

11.1.4     Asia Pacific: RNAi Therapeutics Market, by Application, 2018–2027 (USD Million)

11.1.5     Asia Pacific: RNAi Therapeutics Market, by Route of Administration, 2018–2027 (USD Million)

11.1.6     Asia Pacific: RNAi Therapeutics Market, by End User, 2018–2027 (USD Million)

11.1.7     Asia Pacific: RNAi Therapeutics Market, by Country, 2018 & 2027 (%)

11.1.8     China: RNAi Therapeutics Market – Revenue and Forecast to 2027 (USD Million)

11.1.8.1       China: RNAi Therapeutics Market – Revenue and Forecast to 2027 (USD Million)

11.1.8.2       China: RNAi Therapeutics Market, by Molecule Type, 2018–2027 (USD Million)

11.1.8.3       China: RNAi Therapeutics Market, by Application, 2018–2027 (USD Million)

11.1.8.4       China RNAi Therapeutics Market, by Route of Administration, 2018–2027 (USD Million)

11.1.8.5       China RNAi Therapeutics Market, by End User, 2018–2027 (USD Million)

11.1.9     Japan: RNAi Therapeutics Market – Revenue and Forecast to 2027 (USD Million)

11.1.9.1       Japan: RNAi Therapeutics Market – Revenue and Forecast to 2027 (USD Million)

11.1.9.2       Japan: RNAi Therapeutics Market, by Molecule Type, 2018–2027 (USD Million)

11.1.9.3       Japan: RNAi Therapeutics Market, by Application, 2018–2027 (USD Million)

11.1.9.4       Japan RNAi Therapeutics Market, by Route of Administration, 2018–2027 (USD Million)

11.1.9.5       Japan RNAi Therapeutics Market, by End User, 2018–2027 (USD Million)

11.1.10   India: RNAi Therapeutics Market – Revenue and Forecast to 2027 (USD Million)

11.1.10.1    India: RNAi Therapeutics Market – Revenue and Forecast to 2027 (USD Million)

11.1.10.2    India: RNAi Therapeutics Market, by Molecule Type, 2018–2027 (USD Million)

11.1.10.3    India: RNAi Therapeutics Market, by Application, 2018–2027 (USD Million)

11.1.10.4    India RNAi Therapeutics Market, by Route of Administration, 2018–2027 (USD Million)

11.1.10.5    India RNAi Therapeutics Market, by End User, 2018–2027 (USD Million)

11.1.11   South Korea: RNAi Therapeutics Market – Revenue and Forecast to 2027 (USD Million)

11.1.11.1    South Korea: RNAi Therapeutics Market – Revenue and Forecast to 2027 (USD Million)

11.1.11.2    South Korea: RNAi Therapeutics Market, by Molecule Type, 2018–2027 (USD Million)

11.1.11.3    South Korea: RNAi Therapeutics Market, by Application, 2018–2027 (USD Million)

11.1.11.4    South Korea RNAi Therapeutics Market, by Route of Administration, 2018–2027 (USD Million)

11.1.11.5    South Korea RNAi Therapeutics Market, by End User, 2018–2027 (USD Million)

11.1.12   Australia: RNAi Therapeutics Market – Revenue and Forecast to 2027 (USD Million)

11.1.12.1    Australia: RNAi Therapeutics Market – Revenue and Forecast to 2027 (USD Million)

11.1.12.2    Australia: RNAi Therapeutics Market, by Molecule Type, 2018–2027 (USD Million)

11.1.12.3    Australia: RNAi Therapeutics Market, by Application, 2018–2027 (USD Million)

11.1.12.4    Australia RNAi Therapeutics Market, by Route of Administration, 2018–2027 (USD Million)

11.1.12.5    Australia RNAi Therapeutics Market, by End User, 2018–2027 (USD Million)

12.       Impact of COVID-19 Pandemic on Asia Pacific RNAi therapeutics Market

12.1      Asia Pacific: Impact Assessment of COVID-19 Pandemic

13.       Company Profiles

13.1      Benitec Biopharma

13.1.1     Key Facts

13.1.2     Business Description

13.1.3     Products and Services

13.1.4     Financial Overview

13.1.5     SWOT Analysis

13.1.6     Key Developments

13.2      Olix Pharmaceuticals, Inc.

13.2.1     Key Facts

13.2.2     Business Description

13.2.3     Products and Services

13.2.4     Financial Overview

13.2.5     SWOT Analysis

13.2.6     Key Developments

13.3      GlaxoSmithKline plc.

13.3.1     Key Facts

13.3.2     Business Description

13.3.3     Products and Services

13.3.4     Financial Overview

13.3.5     SWOT Analysis

13.3.6     Key Developments

13.4      Alnylam Pharmaceuticals, Inc.

13.4.1     Key Facts

13.4.2     Business Description

13.4.3     Products and Services

13.4.4     Financial Overview

13.4.5     SWOT Analysis

13.4.6     Key Developments

13.5      Arrowhead Pharmaceuticals, Inc

13.5.1     Key Facts

13.5.2     Business Description

13.5.3     Products and Services

13.5.4     Financial Overview

13.5.5     SWOT Analysis

13.5.6     Key Developments

14.       Appendix

14.1      About The Insight Partners

14.2      Glossary of Terms

LIST OF TABLES

Table 1.            Asia Pacific RNAi therapeutics Market Revenue and Forecasts To 2027, By Molecule Type (US$ Mn)

Table 2.            Asia Pacific RNAi therapeutics Market Revenue and Forecasts To 2027, By Application (US$ Mn)

Table 3.            Asia Pacific RNAi therapeutics Market Revenue and Forecasts To 2027, By Route of Administration (US$ Mn)

Table 4.            Asia Pacific RNAi Therapeutics Market Revenue and Forecasts To 2027, By End-User (US$ Mn)

Table 5.            Asia Pacific RNAi Therapeutics Market, by Molecule Type– Revenue and Forecast to 2027 (USD Million)

Table 6.            Asia Pacific RNAi Therapeutics Market, by Application – Revenue and Forecast to 2027 (USD Million)

Table 7.            Asia Pacific RNAi Therapeutics Market, by Route of Administration – Revenue and Forecast to 2027  (USD Million)

Table 8.            Asia Pacific RNAi Therapeutics Market, by End User – Revenue and Forecast to 2027 (USD Million)

Table 9.            China RNAi Therapeutics Market, by Molecule Type – Revenue and Forecast to 2027 (USD Million)

Table 10.          China RNAi Therapeutics Market, by Application – Revenue and Forecast to 2027 (USD Million)

Table 11.          China RNAi Therapeutics Market, by Route of Administration – Revenue and Forecast to 2027 (USD Million)

Table 12.          China RNAi Therapeutics Market, by End User – Revenue and Forecast to 2027 (USD Million)

Table 13.          Japan RNAi Therapeutics Market, by Molecule Type – Revenue and Forecast to 2027 (USD Million)

Table 14.          Japan RNAi Therapeutics Market, by Application – Revenue and Forecast to 2027 (USD Million)

Table 15.          Japan RNAi Therapeutics Market, by Route of Administration – Revenue and Forecast to 2027 (USD Million)

Table 16.          Japan RNAi Therapeutics Market, by End User – Revenue and Forecast to 2027 (USD Million)

Table 17.          India RNAi Therapeutics Market, by Molecule Type – Revenue and Forecast to 2027 (USD Million)

Table 18.          India RNAi Therapeutics Market, by Application – Revenue and Forecast to 2027 (USD Million)

Table 19.          India RNAi Therapeutics Market, by Route of Administration – Revenue and Forecast to 2027 (USD Million)

Table 20.          India RNAi Therapeutics Market, by End User – Revenue and Forecast to 2027 (USD Million)

Table 21.          South Korea RNAi Therapeutics Market, by Molecule Type – Revenue and Forecast to 2027 (USD Million)

Table 22.          South Korea RNAi Therapeutics Market, by Application – Revenue and Forecast to 2027 (USD Million)

Table 23.          South Korea RNAi Therapeutics Market, by Route of Administration – Revenue and Forecast to 2027  (USD Million)

Table 24.          South Korea RNAi Therapeutics Market, by End User – Revenue and Forecast to 2027 (USD Million)

Table 25.          Incidence, Mortality and Prevalence by cancer site, Australia, 2018

Table 26.          Australia RNAi Therapeutics Market, by Molecule Type – Revenue and Forecast to 2027 (USD Million)

Table 27.          Australia RNAi Therapeutics Market, by Application – Revenue and Forecast to 2027 (USD Million)

Table 28.          Australia RNAi Therapeutics Market, by Route of Administration – Revenue and Forecast to 2027 (USD Million)

Table 29.          Australia RNAi Therapeutics Market, by End User – Revenue and Forecast to 2027 (USD Million)

Table 30.          Glossary of Terms, RNAi Therapeutics Market

 

LIST OF FIGURES

Figure 1.           RNAi Therapeutics Market Segmentation

Figure 2.           Asia Pacific RNAi Therapeutics Market Overview

Figure 3.           Small Interfering RNAs (siRNA) Molecule Type Segment Held Largest Share of RNAi Therapeutics Market

Figure 4.           China is Expected to Show Remarkable Growth During the Forecast Period

Figure 5.           Asia Pacific RNAi Therapeutics Market - Leading Country Markets (US$ Mn)

Figure 6.           RNAi Therapeutics Market - Asia Pacific PEST Analysis

Figure 7.           RNAi Therapeutics Market Impact Analysis of Driver and Restraints

Figure 8.           Asia Pacific RNAi Therapeutics Market – Revenue Forecasts and Analysis – 2019- 2027

Figure 9.           Asia Pacific RNAi Therapeutics Market, By Molecule Type 2019 & 2027 (%)

Figure 10.        Asia Pacific Small Interfering RNAs (siRNA) Market Revenue and Forecasts to 2027 (US$ Mn)

Figure 11.        Asia Pacific MicroRNA (miRNA) Market Revenue and Forecasts to 2027 (US$ Mn)

Figure 12.        Asia Pacific RNAi therapeutics Market, By Application 2019 & 2027 (%)

Figure 13.        Asia Pacific Genetic Disorders Market Revenue and Forecasts to 2027 (US$ Mn)

Figure 14.        Asia Pacific Oncology Market Revenue and Forecasts to 2027 (US$ Mn)

Figure 15.        Asia Pacific Neurodegenerative Disorders Market Revenue and Forecasts to 2027 (US$ Mn)

Figure 16.        Asia Pacific Cardiovascular Disorders Market Revenue and Forecasts to 2027 (US$ Mn)

Figure 17.        Asia Pacific Respiratory Disorders Market Revenue and Forecasts to 2027 (US$ Mn)

Figure 18.        Asia Pacific Infectious Diseases Market Revenue and Forecasts to 2027 (US$ Mn)

Figure 19.        Asia Pacific Renal Diseases Market Revenue and Forecasts to 2027 (US$ Mn)

Figure 20.        Asia Pacific Other Disorders Market Revenue and Forecasts to 2027 (US$ Mn)

Figure 21.        Asia Pacific RNAi therapeutics Market, By Route of Administration 2019 & 2027 (%)

Figure 22.        Asia Pacific Intradermal Injections Market Revenue and Forecasts to 2027 (US$ Mn)

Figure 23.        Asia Pacific Pulmonary Delivery Market Revenue and Forecasts to 2027 (US$ Mn)

Figure 24.        Asia Pacific Intravenous Injections Market Revenue and Forecasts to 2027 (US$ Mn)

Figure 25.        Asia Pacific Intraperitoneal Injections Market Revenue and Forecasts to 2027 (US$ Mn)

Figure 26.        Asia Pacific Other Route of Administrations Market Revenue and Forecasts to 2027 (US$ Mn)

Figure 27.        Asia Pacific RNAi Therapeutics Market, by End-User 2019 & 2027 (%)

Figure 28.        Asia Pacific Diagnostic Laboratories Market Revenue and Forecasts to 2027 (US$ Mn)

Figure 29.        Asia Pacific Research and Academic Laboratories Mark et Revenue and Forecasts to 2027 (US$ Mn)

Figure 30.        Asia Pacific Hospitals Market Revenue and Forecasts to 2027 (US$ Mn)

Figure 31.        Asia Pacific: RNAi Therapeutics Market, by Key Country – Revenue (2019) (USD Million)

Figure 32.        Asia Pacific RNAi Therapeutics Market Revenue and Forecast to 2027 (USD Million)

Figure 33.        China: RNAi Therapeutics Market – Revenue and Forecast to 2027 (USD Million)

Figure 34.        Japan: RNAi Therapeutics Market – Revenue and Forecast to 2027 (USD Million)

Figure 35.        India: RNAi Therapeutics Market – Revenue and Forecast to 2027 (USD Million)

Figure 36.        South Korea: RNAi Therapeutics Market – Revenue and Forecast to 2027 (USD Million)

Figure 37.        Australia: RNAi Therapeutics Market – Revenue and Forecast to 2027 (USD Million)

Figure 38.        Impact of COVID-19 Pandemic in Asia-Pacific Country Markets

 

  1. Benitec Biopharma
  2. Olix Pharmaceuticals, Inc.
  3. GlaxoSmithKline plc
  4. Alnylam Pharmaceuticals, Inc.
  5. Arrowhead Pharmaceuticals, Inc
  • It provides understanding of the Asia Pacific RNAi therapeutics market landscape and identifies RNAi therapeutics market segments that are most likely to guarantee a strong return
  • It guides to stay ahead of the race by comprehending the ever-changing competitive landscape for the Asia Pacific RNAi therapeutics market
  • It helps efficiently plan merger and acquisition and partnership deals in the RNAi therapeutics market by identifying market segments with the most promising probable sales
  • It facilitates knowledgeable business decision-making through perceptive and comprehensive analysis of various segments pertaining to the Asia Pacific RNAi therapeutics market.
  • It provides revenue forecast of the market based on various segments for the period from 2019 to 2027
TIPRE00015147
Your data will never be shared with third parties, however, we may send you information from time to time about our products that may be of interest to you. By submitting your details, you agree to be contacted by us. You may contact us at any time to opt-out.

Pricing